ADC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports 89.8% Response Rate in ZYNLONTA and Glofitamab Phase 1b Trial for r/r DLBCL
ADC Therapeutics SA has announced updated results from the ongoing LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). As of the November 17, 2025, data cutoff, 49 patients were efficacy evaluable with a minimum of six months of follow-up. The best overall response rate $(ORR)$ was 89.8%, with a complete response $(CR)$ rate of 77.6%. The combination therapy showed a manageable safety profile, with grade 5 adverse events occurring in 4.1% of patients and cytokine release syndrome $(CRS)$ reported in 36.7% of patients across dose levels. These updated data have already been presented by the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950103-25-015818), on December 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。